Oriza Seed Venture Capital, located in Suzhou Industrial Park, is held by Suzhou Oriza Holdings Ltd. Oriza Seed is a market-oriented investment platform. It looks for investment opportunities among early-stage and growth-stage enterprises in the fields of Healthcare and TMT. Oriza Seed has ample resources and experiences investing in the healthcare field. By late March 2016, Oriza Seed has invested in more than 50 healthcare companies, including Ascentage Pharma, Innovent Biologics, and SceneRay Corporation.

Oriza Seed Capital (Oriza Yuandian)

Decheng Capital is an investment firm that provides capital and strategic support to life science companies with revolutionary technologies and growth-stage healthcare companies with a strong market presence. It is a group of dedicated professionals with complementary expertise who have outstanding track records of building highly successful companies globally. Founded in 2012, Decheng continues to capitalize on a historic opportunity in the rapid growth of the healthcare industry as well as breakthroughs in life science research. With over $2 billion in capital under management and support from some of the most prestigious LPs in the world, Decheng is poised to deliver superior returns for our investors and create value for our entrepreneur partners.

Decheng Capital

3E Bioventures Capital is a healthcare focused venture investment fund. The core 3E investment team members are all trained in biomedical fields, with healthcare industry experience and years of successful investment or entrepreneurship experience in China. The 3E team combines good global industry perspectives with practical on the ground China experiences, the team’s past investment portfolio companies cover areas such as drug, device, diagnostics, healthcare IT and medical services. 3E Bioventures Capital currently manages both RMB and US Dollar funds, investing in early and growing stage companies in China and overseas. They believe in the huge industry growth and significant investment opportunities in China healthcare space for the next 10 to 20 years. They aim to leverage their healthcare expertise and experience to ride this historic opportunity, to help build successful healthcare ventures and technologies, to generate good return for their investors, and at the same time, to build 3E Bioventures into a significant international healthcare investment brand.

3E Bioventures

Trend Investment Group is a private equity firm. Trend Investment Group focuses on seed-stage, early-stage, and later-stage healthcare and technology firms.

Trend Investment Group

SDIC Fund Management is a private equity that manages funds and raises nearly 60 billion yuan at present.  The management funds cover financial institutions, social security funds, state-owned and private capital, and it is one of the largest professional private equity management institutions in China.

SDIC Fund Management

Sherpa Venture Capital is an investment firm that focuses on the investment and cultivation of the Pharmaceutical and Biotech industry. It also specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where they have established robust portfolio sources, lasting value-adding cooperations and relationships,  as well as mature all-cycle services with key resources.  It was founded in 2018 and is headquartered in Beijing, China.

Sherpa Healthcare Partners

South China Venture Capital is a private equity investment fund management as the main business of professional investment management organization. Under the jurisdiction of the three branch of the fund management company: Shenzhen South China Invsetment Management Co.Ltd, South China (Tianjin) Equity Investment Fund Management Co. Ltd., Shenzhen Zhongnan Hongyuan Invsetment Management Co. Ltd.

South China Venture Capital

CMB International Capital Corporation is an investment banking firm that offers comprehensive professional services and financial advisory services. It provides mergers and acquisitions, initial public offering, equity underwriting, company restructuring, project financing, and business consulting services.  CMB International Capital Corporation provides corporate finance, asset management, wealth management and securities brokerage services. Additionally, it offers debt financing and transaction advisory services, placement of shares and refinancing for listed companies.  CMB International Capital Corporation’s clientele include institutional, corporate and individual customers both domestic and overseas. It began operation in 1987, with its headquarters in Central in Hong Kong as a subsidiary of China Merchants Bank.

CMB International Capital Corporation

MiraeAsset Financial Group is an investment firm.

MiraeAsset Financial Group

Founded in 2003, Hony Capital is a pioneer in China’s home grown private equity industry. Sponsored by Legend Holdings, a leading Chinese conglomerate, Hony has blazed the trail in formulating private equity investment strategies suitable for Chinese conditions by combining a deep understanding of local environment and people with global resources and international best practices. Today, with over USD 6.8 billion in assets under management across 7 funds and investments in over 60 companies, Hony is a leading China-focused private equity firm.   Adhering to the “value creation” investment philosophy, Hony partners with managers and entrepreneurs to build their businesses into sustainable leaders in respective industries. Hony focuses on sectors where it has developed expertise: pharmaceuticals and healthcare, consumer & retail, media & entertainment, financial services, construction materials, machinery, and alternative energy & resources

Hony Capital

Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace.

Cormorant Asset Management

Best-in-class investments mainly in the U.S. medical devices technology, as well as biotech, and mobile healthcare sectors through early sta

Shangbay Capital

Hidragon Capital

Octagon Capital invests in public and private healthcare companies globally. Octagon Capital focuses on strategic long-term investments and strive to work with our portfolio management teams as partners.

Octagon Capital Advisors

''Yan Chuang Capital'', the full name of ''Yanyuan Innovation Capital Group'', was founded in June 2010, formerly known as ''Yanyuan Capital Group''. A high-tech enterprise investment and capital operation platform co-sponsored by Peking University alumni who have transformed achievements. Yanchuang Capital always takes value investment as the core, adhering to the corporate philosophy of ''Integrity and character, customer-centered, and ultimate work'', based on the excavation of China's outstanding achievements in the historical trend of economic growth, technological catch-up, and corporate growth. Enterprises and entrepreneurs; take capital as the main channel and provide empowerment services, and create greater value for investors through common growth and win-win development with outstanding enterprises and entrepreneurs.

Yanchuang Capital

EpimAb Biotherapeutics

EpimAb Biotherapeutics is a privately owned biopharmaceutical company dedicated to generating novel bi-specific antibody therapeutics based on its proprietary FIT-Ig (Fabs-In-Tandem) platform.  Monoclonal antibodies have transformed the treatment of human diseases, including inflammatory and autoimmune diseases, cancer, severe infections and many rare conditions over the course of the past two decades. Bi-specific antibodies are engineered from two different monoclonal antibodies and combine their key features into one molecule. As a novel drug class, bi-specifics provide additional options for the treatment of many life-threatening diseases such as cancer. However, even minor modifications to any pharmaceutically active biologic such as an antibody can significantly change the properties critical to its development, such as its binding properties, the pharmacokinetics, its stability, solubility and the ability to produce it in sufficient quantities at reasonable costs. This challenge has prevented a majority of bi-specific antibodies of potential interest to scientists and clinicians from advancing into clinical development because their drug-like features were compromised. Thus, the need for a new generation of bi-specific antibody therapeutics in the pharmaceutical industry remains high.

EpimAb Biotherapeutics is a clinical-stage biotechnology company headquartered in Shanghai, China. It specializes in developing bispecific antibodies for treating various types of cancers and immune-related disorders. The company utilizes its proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) and Monovalent Asymmetric Tandem Fab (MAT-Fab) platforms to generate bispecific antibodies.

EpimAb Biotherapeutics to Present Initial First-in-human Data of EMB-02 at the 2023 ESMO Conference

Almirall licenses bispecific platform

EpimAb Biotherapeutics to Present Late-breaking Abstract on Preclinical Results of EMB-07 at the 2024 American Association for Cancer Research Annual Meeting

EMB-09 by EpimAb Biotherapeutics for Metastatic Ovarian Cancer: Likelihood of Approval

EMB-07 by EpimAb Biotherapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

EpimAb Biotherapeutics Appoints Yonghong Zhu, M.D., Ph.D., as Chief Medical Officer

EpimAb Biotherapeutics and Almirall Announce Bispecific Antibody License Agreement

EMB-07 by EpimAb Biotherapeutics for Bladder Cancer: Likelihood of Approval

EpimAb Biotherapeutics to Present a Late-Breaking Abstract of First-in-Human Data of EMB-06 at 2023 SITC Annual Meeting

EpimAb Biotherapeutics Announces U.S. FDA Clearance of IND Application for Phase Ib/II Trial of EMB-01 in Combination with Tagrisso® for Non-Small Cell Lung Cancer

07 by EpimAb Biotherapeutics for Bladder Cancer: Likelihood of Approval – MEEFRO

Targeting complex diseases with complex molecules

Large-molecule Therapeutics

Candid Therapeutics and EpimAb Biotherapeutics Enter Into Research Collaboration to Discover and Develop Novel T-Cell Engagers for Autoimmune Indications

EpimAb Biotherapeutics is a clinical-stage biotechnology company headquartered in Shanghai, China. It specializes in developing bispecific antibodies for treating various types of cancers and immune-related disorders. The company utilizes its proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) and Monovalent Asymmetric Tandem Fab (MAT-Fab) platforms to generate bispecific antibodies.
EpimAb's lead candidate, EMB-01, is a bispecific antibody targeting EGFR and cMET. It is currently being evaluated in Phase I/II clinical trials for non-small cell lung cancer (NSCLC) and several gastrointestinal indications in the US and China. In June 2022, the US FDA cleared an IND application for a Phase Ib/II trial investigating EMB-01 in combination with Tagrisso (osimertinib) for NSCLC patients with EGFR mutations.
Another notable candidate is EMB-02, a bispecific antibody targeting PD-1 and LAG-3 checkpoint proteins. Initial data from a Phase I dose escalation study in advanced solid tumors were presented at the 2023 ESMO Congress in October 2023. EMB-06, a novel 2+2 BCMA×CD3 T-cell engaging bispecific antibody, demonstrated lower levels of cytokine release in preclinical and clinical studies. Early results from a Phase I study in relapsed or refractory multiple myeloma were presented at the 2023 SITC Annual Meeting in November 2023.
In March 2024, EpimAb announced the acceptance of a late-breaking abstract featuring preclinical results of EMB-07, a novel ROR1×CD3 T-cell engager, at the 2024 AACR Annual Meeting. EMB-07 is currently being evaluated in a Phase I trial in solid tumors and lymphomas.
In October 2023, EpimAb entered a license agreement with Almirall, granting the latter global rights to develop and commercialize up to three bispecific antibodies using EpimAb's FIT-Ig platform for immune-related disorders in dermatology.

Innovent Biologics is a leading biopharmaceutical company founded in 2011 with the mission to develop and commercialize innovative and affordable medicines. The company focuses on oncology, cardiovascular and metabolic diseases, autoimmune disorders, and ophthalmology. As of March 2024, Innovent has ten approved products in the Chinese market, including TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), and others. The company's core product, TYVYT, is an anti-PD-1 monoclonal antibody approved across seven indications, making it the most widely approved PD-1 inhibitor in China.
Innovent has a robust pipeline with three new drug applications under review, four assets in Phase III or pivotal trials, and 19 molecules in early clinical development. The company's innovative pipeline spans various modalities, including bispecific antibodies, antibody-drug conjugates (ADCs), and RNA therapeutics. In oncology, Innovent is advancing the next-generation immunotherapy combinations with ADCs, such as the CLDN18.2 ADC (IBI343) and the EGFR/B7H3 bispecific ADC (IBI3001). The company's metabolic pipeline includes mazdutide, a first-in-class GLP-1R/GCGR dual agonist in late-stage development for weight management.
Innovent has a strong emphasis on global innovation, with its Innovent Academy delivering eight novel molecules into IND-enabling stage in 2023. The company has established large-scale manufacturing facilities in Suzhou and Hangzhou to support global supply. Innovent collaborates with over 30 global healthcare leaders, reinforcing its commitment to advancing biopharmaceutical innovation worldwide.

Innovent Biologics

<div>
 
 ADC Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing next-generation antibody-drug conjugates (ADCs) for treating cancer. The company's ADCs leverage highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology, which causes the ADCs' antibodies to bind to specific tumor cell surface antigens. Once internalized, the potent PBD dimer is released inside the cell, creating covalent cross-links between the DNA strands, disrupting cell division without triggering DNA repair mechanisms.
 
 
 
 
 ADC Therapeutics' lead product candidate, Zynlonta, received FDA approval in April 2021 for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. The company is also advancing a deep pipeline of other PBD-based ADCs targeting hematologic malignancies and solid tumors. As of May 2021, ADC Therapeutics reported revenues of USD 38.2 million, reflecting initial sales of Zynlonta.
 
 
 
 
 In March 2022, ADC Therapeutics acquired US commercial rights to Overrkey Biological's anti-HER2 ADC Overena, broadening its cancer treatment portfolio. The acquisition aligned with the company's strategic focus on expanding globally with its PBD-based ADC technology.
 
</div>

ADC Therapeutics

Sirnaomics is a biopharmaceutical company engaged in the discovery and development of RNA therapeutics. The company focuses on innovative drugs for indications with unmet medical needs and large market opportunities. Sirnaomics utilizes two proprietary delivery platforms: the Polypeptide Nanoparticle Formulation (PNP) and the second generation of GalNAc conjugates called GalAhead.
Sirnaomics has established a robust pipeline of drug candidates, with several products in clinical and preclinical stages. The company's lead clinical product, STP705, has demonstrated positive results in Phase II clinical trials for the treatment of squamous cell carcinoma in situ (isSCC) and basal cell carcinoma (BCC). Additionally, STP705 is being explored for focal fat reduction in the medical aesthetics field. Another promising candidate, STP707, is a PNP formulation consisting of two siRNAs targeting TGF-β1 and COX-2 for intravenous treatment of solid tumors. STP707 has shown promising results in a Phase I basket clinical study, exhibiting stable disease response in 74% of evaluable patients.
Sirnaomics achieved a significant milestone by advancing STP122G, the first candidate utilizing the GalAhead technology, into clinical development. STP122G targets Factor XI for anticoagulation therapeutics and is currently undergoing Phase I clinical trials.
In March 2023, Sirnaomics' subsidiary, RNAimmune, received IND clearance from the FDA to initiate a Phase I clinical trial for RV-1770, an mRNA vaccine targeting respiratory syncytial virus (RSV). Additionally, RNAimmune obtained FDA clearance for a SARS-CoV-2 vaccine booster candidate, RV-1730.
Sirnaomics has established its manufacturing facility in China, enabling the transition from a biotech company to a biopharmaceutical corporation. The facility has successfully produced a full GMP batch of STP707 for human injection and is expected to support the company's clinical pipeline.
In July 2024, Sirnaomics announced the completion of IND-enabling studies for STP125G, an siRNA therapeutic targeting Apolipoprotein C3 (ApoC3) for the treatment of cardiovascular diseases. The positive results from non-human primate studies support the filing of an IND with the FDA.

Sirnaomics

Sesen Bio is a late-stage clinical company that previously focused on developing targeted fusion protein therapeutics for cancer treatment. Its lead product candidate, Vicineum, is a locally administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive bladder cancer (NMIBC).
In February 2021, the FDA accepted Sesen Bio's Biologics License Application (BLA) for Vicineum to treat BCG-unresponsive NMIBC, granting Priority Review. However, in August 2021, the company received a Complete Response Letter from the FDA, requiring an additional Phase 3 clinical trial for potential resubmission. Following discussions with the FDA in March 2022, Sesen Bio aligned on most elements for the trial design and planned to meet again in mid-2022 to finalize outstanding items.
On July 15, 2022, Sesen Bio made the strategic decision to voluntarily pause further development of Vicineum in the US due to the incremental timeline and costs associated with the additional Phase 3 trial. The company shifted its primary focus to consummating a strategic transaction to maximize shareholder value while seeking a partner for Vicineum's further development.
In September 2022, Sesen Bio announced a pending merger with Carisma Therapeutics, a clinical-stage biopharmaceutical company developing immunotherapies based on engineered macrophages. This merger was approved by Sesen Bio's stockholders in March 2023, with the combined company operating under the name Carisma Therapeutics Inc. and trading on the Nasdaq under the ticker "CARM".
Upon closing the merger in March 2023, Sesen Bio declared a special cash dividend of USD 75 million (around USD 0.36 per share) to its stockholders and issued them Contingent Value Rights (CVRs) entitling them to potential proceeds from the sale of Vicineum and other assets, as well as a USD 30 million milestone payment under the Roche Asset Purchase Agreement.

Sesen Bio

ACELYRIN, INC. is a late-stage clinical biopharmaceutical company focused on developing transformative medicines for immunology and inflammatory diseases. The company's lead product candidate is izokibep, a next-generation inhibitor of interleukin-17A (IL-17A) designed to overcome limitations of monoclonal antibodies. Izokibep is being evaluated in multiple late-stage trials for moderate-to-severe hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and noninfectious uveitis.
In March 2024, ACELYRIN reported positive top line data from a global Phase 2 billion/3 clinical trial of izokibep in PsA, meeting the primary endpoint of ACR50 at 16 weeks with high statistical significance. The trial also demonstrated robust clinical responses for higher hurdle endpoints like ACR70, PASI100, and composite measures, indicating izokibep's potential to provide clinically meaningful benefits. Additionally, ACELYRIN announced differentiated long-term 32-week data from a global Phase 2 billion trial of izokibep in HS, showing rapid, dose-ordered improvement across multiple disease manifestations, including HiSCR100 achieved earlier than reported by other IL-17 inhibitors.
ACELYRIN's other late-stage asset is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of thyroid eye disease (TED). In March 2024, ACELYRIN announced positive proof-of-concept data from a Phase 1/2 trial, demonstrating rapid improvements in proptosis and clinical activity score within three weeks after the first dose.
As of December 31, 2023, ACELYRIN had cash, cash equivalents, and short-term marketable securities totaling USD 721.3 million, providing a runway to support key late-stage data milestones and registrational studies across multiple indications. In January 2023, ACELYRIN acquired ValenzaBio, adding lonigutamab and other immunology assets to its pipeline.

ACELYRIN

Companies that develop engineered proteins that can target specific proteins or cells in the body

Companies that develop large molecules that can be used to target specific RNA molecules in the body, either to silence or replace them

Companies that develop large molecules that combine the targeting ability of monoclonal antibodies with the cytotoxic effects of chemotherapy drugs

Companies that develop large molecules that can be used to replace or supplement deficient or malfunctioning proteins in the body

Companies specializing in peptide-based treatments leverage short amino acid chains, known as peptides, to target and modulate various biological processes for therapeutic applications

AL/ML used to identify potential drug targets, and support protein engineering and optimization

EpimAb Biotherapeutics

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless